Core Viewpoint - The company, TianKang (301263.SZ), has received a notice of acceptance for the production registration application of Indobufen Tablets from the National Medical Products Administration (NMPA) of China, indicating progress in its drug approval process [1]. Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1]. - The NMPA has reviewed the application according to Article 32 of the Administrative Licensing Law of the People's Republic of China and has decided to accept the application [1]. Group 2: Product Information - Indobufen Tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risks [1]. - The drug is intended for use in ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis formation, and it can also be used to prevent thrombosis during hemodialysis [1].
泰恩康(301263.SZ)：吲哚布芬片收到药品注册受理通知书